Anti-vascular endothelial growth factor (VEGF) therapies have proven efficacy in age-related macular degeneration (AMD), including the ability to not only minimize further visual acuity loss, but to actually improve mean visual acuity. Although the development of these therapies has signaled a new era in the treatment of AMD, the required frequency of injections is a burden to many patients and their caregivers. Recent studies have compared the patient risk and treatment burden associated with various timed and individualized treatment protocols to determine their effects on long-term visual outcomes. As retina specialists consider these results when designing the optimal management plan for each patient, many questions remain, such as "What is the optimal therapy, frequency of treatment, and monitoring schedule?"

This activity will discuss the burden of current treatment regimens on patients and their caregivers, review the latest clinical data, and examine emerging treatment options, focusing on injection frequency and schedule monitoring. Specialized case study discussions that cover practical application of the different treatment options will be featured. Ultimately, this activity aims to assist retina specialists in developing optimal management strategies that improve visual acuity for their patients with neovascular AMD.

This activity is designed to enhance the retina specialist's understanding of current and emerging strategies for optimal treatment of neovascular AMD.

This activity is designed for retina specialists in attendance at the ASRS 29th Annual Meeting. No prerequisites required.

Quan Dong Nguyen, MD, MSc (Course Director)
Associate Professor of Ophthalmology
Retina Division Wilmer Eye Institute
Johns Hopkins University School of Medicine
Baltimore, Maryland

David M. Brown, MD, FACS
Retina Consultants of Houston
Clinical Associate Professor
The Methodist Hospital–Weill Cornell Medical College
Houston, Texas

Diana V. Do, MD
Associate Professor of Ophthalmology
Retina Division
Wilmer Eye Institute
Johns Hopkins University School of Medicine
Baltimore, Maryland

Allen C. Ho, MD, FACS
Attending Surgeon
Wills Eye Institute
Professor of Ophthalmology
Thomas Jefferson University School of Medicine
Philadelphia, Pennsylvania

After attending this activity, participants will demonstrate the ability to:

• EVALUATE the effect of dosing and treatment strategies based on the efficacy and safety of current and emerging therapies for the management of neovascular AMD.
• ASSESS and comprehend systematically the results of the latest clinical trials for the management of neovascular AMD.

Accreditation Statement — The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement — The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure —It is the policy of the Johns Hopkins University School of Medicine that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosures will be made in the course handout materials.

Privacy Statement —The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine's CME program. CME collects only the information necessary to provide you with the services that you request.

CONFIDENTIALITY DISCLAIMER FOR CME CONFERENCE ATTENDEES
I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Johns Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person's health or treatment that identifies the person. I also understand that while I am participating in this capacity I will be treated as a temporary member of Johns Hopkins for purposes of the Privacy Regulations only.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-502-7983, e-mail: HIPAA@jhmi.edu.

"The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only."

Johns Hopkins University School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03)

Americans with Disabilities Act (ADA)
The Johns Hopkins University School of Medicine fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs.

Fee Information: There is no fee for this educational activity.